全文获取类型
收费全文 | 7154篇 |
免费 | 293篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 180篇 |
妇产科学 | 111篇 |
基础医学 | 792篇 |
口腔科学 | 111篇 |
临床医学 | 364篇 |
内科学 | 1625篇 |
皮肤病学 | 82篇 |
神经病学 | 693篇 |
特种医学 | 181篇 |
外科学 | 1234篇 |
综合类 | 28篇 |
预防医学 | 202篇 |
眼科学 | 228篇 |
药学 | 511篇 |
中国医学 | 19篇 |
肿瘤学 | 1058篇 |
出版年
2023年 | 39篇 |
2022年 | 66篇 |
2021年 | 100篇 |
2020年 | 70篇 |
2019年 | 110篇 |
2018年 | 119篇 |
2017年 | 91篇 |
2016年 | 130篇 |
2015年 | 114篇 |
2014年 | 148篇 |
2013年 | 190篇 |
2012年 | 291篇 |
2011年 | 336篇 |
2010年 | 215篇 |
2009年 | 163篇 |
2008年 | 367篇 |
2007年 | 344篇 |
2006年 | 416篇 |
2005年 | 434篇 |
2004年 | 449篇 |
2003年 | 455篇 |
2002年 | 446篇 |
2001年 | 192篇 |
2000年 | 201篇 |
1999年 | 204篇 |
1998年 | 141篇 |
1997年 | 105篇 |
1996年 | 94篇 |
1995年 | 83篇 |
1994年 | 66篇 |
1993年 | 73篇 |
1992年 | 140篇 |
1991年 | 123篇 |
1990年 | 123篇 |
1989年 | 91篇 |
1988年 | 86篇 |
1987年 | 74篇 |
1986年 | 65篇 |
1985年 | 51篇 |
1984年 | 49篇 |
1983年 | 46篇 |
1982年 | 37篇 |
1981年 | 24篇 |
1980年 | 23篇 |
1979年 | 37篇 |
1978年 | 23篇 |
1977年 | 28篇 |
1976年 | 25篇 |
1975年 | 20篇 |
1972年 | 22篇 |
排序方式: 共有7482条查询结果,搜索用时 156 毫秒
91.
Takahashi N Shoji T Matsubara K Hitomi H Hashimoto M Kiyomoto H Uchida K Miki S Hirohata M Ishizu T Akiyama K Mizushige K Matsuo H Yuasa S 《Journal of the American Society of Nephrology : JASN》1999,10(5):1090-1094
The effect of histamine H2-receptor antagonist (famotidine) on the phosphorus-binding abilities of calcium carbonate and calcium lactate were examined in 13 chronic hemodialysis patients. In seven patients receiving calcium carbonate, famotidine (20 mg/d) was given because of gastroduodenal disorders, and calcium carbonate was replaced with calcium lactate as a phosphorus binder after 4 wk of treatment with famotidine. With the 4-wk administration of famotidine accompanied by calcium carbonate, the serum phosphorus level increased from 6.3+/-0.9 to 7.1+/-0.5 mg/dl (P<0.05). However, with the substitution of calcium lactate, the serum phosphorus level decreased significantly when compared to that before substitution (6.3+/-0.2 and 6.0+/-0.9 mg/dl after 4 and 8 wk of substitution, respectively), despite continued administration of famotidine. Serum calcium, creatinine, alkaline phosphatase, high sensitive parathyroid hormone, blood urea nitrogen, arterial blood pH, and bicarbonate were not significantly altered during the trial period. In six control patients treated with calcium carbonate alone, there were no statistical changes in serum calcium and phosphorus levels after substitution of calcium lactate for calcium carbonate. These results suggest that famotidine significantly affects the phosphorus-binding ability of calcium carbonate, but not that of calcium lactate. A careful observation of changes in the serum phosphorus level should be required in hemodialysis patients receiving calcium carbonate and histamine H2-receptor antagonists. Calcium lactate may be useful as a phosphorus binder in such hemodialysis patients. 相似文献
92.
Ideyama Y Kudoh M Tanimoto K Susaki Y Nanya T Nakahara T Ishikawa H Fujikura T Akaza H Shikama H 《Japanese journal of pharmacology》1999,79(2):213-220
The concentrations of androstenedione and dehydroepiandrosterone, products of C17-20 lyase, in the medium after a 6-hr incubation of NCI-H295 cells were decreased by YM116 (2-(1H-imidazol-4-ylmethyl)-9H-carbazole) (IC50: 3.6 and 2.1 nM) and ketoconazole (IC50: 54.9 and 54.2 nM). 17Alpha-hydroxyprogesterone, a product of 17alpha-hydroxylase, was increased by YM116 (1-30 nM) and by ketoconazole (10-300 nM) and then was decreased at higher concentrations of both agents (IC50: 180 nM for YM116, 906 nM for ketoconazole), indicating that YM116 and ketoconazole were 50- and 16.5-fold more specific inhibitors of C17-20 lyase, respectively, than 17alpha-hydroxylase. Compatible with these findings, progesterone, a substrate of 17alpha-hydroxylase, was increased by these agents. Cortisol production was inhibited by YM116 and ketoconazole (IC50: 50.4 and 80.9 nM, respectively). YM116 was a 14-fold more potent inhibitor of androstenedione production than cortisol production, whereas ketoconazole was a nonselective inhibitor of the production of both steroids. YM116 and ketoconazole inhibited the C17-20 lyase activity in human testicular microsomes (IC50: 4.2 and 17 nM, respectively). These results demonstrate that YM116 reduces the synthesis of adrenal androgens by preferentially inhibiting C17-20 lyase activity. 相似文献
93.
Noriyuki Masuda Shunichi Negoro Kouji Takeda Nobuhide Takifuji Tomonori Hirashima Takashi Yana Noriaki Kurata Takashi Kuwabara Satoshi Kobayashi Shinzoh Kudoh Kaoru Matsui Minoru Takada Masahiro Fukuoka 《Investigational new drugs》1999,16(3):245-254
(E)-2-deoxy-2-(fluoromethylene)cytidine (FMdC), one of the most potent inhibitors of ribonucleoside diphosphate reductase, was selected for clinical development because of its novel mechanisms of action, and strong antitumor activity against experimental tumor models. This study was designed to determine the toxicities, maximum-tolerated dose (MTD), and pharmacokinetic profile of FMdC. FMdC was given orally for 5 consecutive days every 3 or 4 weeks in patients with advanced solid tumors. The starting dose was 8 mg/m2/day. Pharmacokinetic studies were carried out on days 1 through 5 of the first cycle. Ten patients with non-small cell lung cancer received 15 courses of FMdC at doses which were de-escalated from 8 mg/m2/day to 2 mg/m2/day because of unexpected severe toxicities at the starting dose level. Neutropenia was the dose-limiting toxicity. Thrombocytopenia and anemia were mild. Flu-like symptoms and fever were the common non-hematologic toxicities. The MTD was 4 mg/m2/day, since four of six patients developed grade 3–4 neutropenia. At the 4 mg/m2/day dose level, the mean terminal half-life, maximum plasma concentration (Cmax), plasma clearance, and mean residence time on day 1 were 3.20 h, 15.8 ng/ml, 2.91 l/h/kg, and 4.03 h, respectively. The recommended dose for phase II studies with this schedule is also 4 mg/m2/day for 5 days. Further investigations are necessary to establish optimal dosing schedules and routes for the administration of FMdC. 相似文献
94.
Shuto T Hirohashi K Ikebe T Mikami S Yamamoto T Kubo S Wakasa K Kinoshita H 《World journal of surgery》2000,24(12):1566-1569
The presence of small additional hepatocellular carcinomas (HCCs) undetectable before hepatic resection is a crucial topic
for hepatic surgeons. We assessed the incidence of pathologically diagnosed multiple HCCs in 267 patients who underwent hepatic
resection for HCC. Ninety-five additional HCC nodules were detected in 72 of the patients (27%). The survival rate of these
72 patients was significant worse than for the 195 with single nodular HCC (p= 0.0013). Twenty-one (22%) were detected before surgery, 29 (31%) during surgery, and 45 (47%) on pathologic examination
after surgery. The mean nodule diameters for each group were 2.1, 1.0, and 0.9 cm, respectively (p < 0.0001). None of the 21 nodules detected before surgery was well differentiated, whereas 30 of the 74 nodules in the other
two groups were well-differentiated. Although the mean nodule diameter of the well-differentiated HCC group was the smallest,
there was no significant difference among the three groups assigned according to tumor differentiation (p= 0.2355). Altogether, 9 of 16 patients with additional nodules detected before surgery (56%) and 49 of 59 with additional
nodules detected during or after surgery (88%) had cirrhosis of the liver. The odds ratio for detecting a new HCC nodule during
or after surgery in the presence of cirrhosis was 5.444 (p= 0.0087). Improvement in the detection of small additional HCC nodules before and during surgery and meticulous follow-up
after surgery are necessary for patients with cirrhosis. For patients without cirrhosis, surgical treatment may be performed
according to the results of preoperative imaging studies. 相似文献
95.
96.
K Nakagawa T Tamura S Negoro S Kudoh N Yamamoto N Yamamoto K Takeda H Swaisland I Nakatani M Hirose R-P Dong M Fukuoka 《Annals of oncology》2003,14(6):922-930
BACKGROUND: This phase I dose-escalating study investigated the tolerability and toxicity of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid tumors. Thirty-one patients were included. PATIENTS AND METHODS: Patients initially received a single oral dose of gefitinib followed by 10-14 days of observation. Oral gefitinib was subsequently administered on 14 consecutive days, every 28 days. Dose escalation was from 50 mg/day to a maximum of 925 mg/day or dose-limiting toxicity (DLT). RESULTS: Most adverse events were mild (grade 1/2); the most frequent were an acne-like rash and gastrointestinal effects. Two of six patients at 700 mg/day had DLT; no further dose escalation occurred. C(max) was reached within 3-7 h and exposure to gefitinib increased with dose. Mean terminal half-life following multiple dosing was 50.1 h (range 27.8-79.7 h). A partial response (duration 35-361 days) was observed in five of the 23 patients with non-small-cell lung cancer over a range of doses (225-700 mg/day), and seven patients with a range of tumors had disease stabilization (duration 40-127 days). CONCLUSIONS: In conclusion, gefitinib showed a favorable tolerability profile in Japanese patients. The safety profile, pharmacokinetic parameters and antitumor activity observed in our study are comparable to those observed in patients from the USA and Europe. 相似文献
97.
Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. 总被引:9,自引:0,他引:9
Shinji Yamamoto Yasuhiko Tomita Yoshihiko Hoshida Shuji Takiguchi Yoshiyuki Fujiwara Takushi Yasuda Masahiko Yano Shoji Nakamori Masato Sakon Morito Monden Katsuyuki Aozasa 《Journal of clinical oncology》2003,21(13):2537-2544
PURPOSE: Valosin-containing protein (VCP; also known as p97) was shown to be associated with antiapoptotic function and metastasis via activation of nuclear factor kappa-B signaling pathway. In this study, association of VCP expression with recurrence of gastric carcinoma (GC), in which lymphatic vessels are the main route of spread, was examined. PATIENTS AND METHODS: VCP expression in 330 patients with GC (242 males and 88 females) with ages ranging from 26 to 81 years (median, 60 years) was analyzed by immunohistochemistry, in which staining intensity in tumor cells was categorized as weaker (level 1) or equal to or stronger (level 2) than that in endothelial cells. RESULTS: Ninety-four (28.7%) patient cases showed level 1 and 233 patient cases (71.3%) showed level 2 VCP expression. Patients with level 2 expression showed higher rates of large tumor size (P <.0001), undifferentiated histologic subtype (P <.05), presence of vascular and lymphatic invasion (P <.0001 for both), presence of lymph node metastasis (P <.0001), deep tumor invasion (P <.0001), and poorer disease-free and overall survivals (P <.0001 for both) compared with those with level 1 VCP expression. Multivariate analysis revealed VCP expression level as an independent prognosticator for disease-free and overall survival. VCP level was an indicator for disease-free and overall survival in the early (pT1; P <.01 and P <.05, respectively) and advanced (pT2-4; P <.05 for both) group of pathologic tumor-node-metastasis system classification. CONCLUSION: The prognostic significance of VCP expression level in GC was demonstrated. 相似文献
98.
Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. 总被引:11,自引:0,他引:11
99.
100.
Targeted Gene Transfer for Adenocarcinoma Using a Combination of Tumor-specific Antibody and Tissue-specific Promoter 总被引:2,自引:0,他引:2
Shuji Kurane John C. Krauss Eiji Watari Reiji Kannagi Alfred E. Chang Shoji Kudoh 《Cancer science》1998,89(11):1212-1219
We have developed a highly specific gene transfer method for adenocarcinoma using a monoclonal antibody against tumor-specific antigen coupled with a plasmid containing the carcinoembryonic antigen (CEA)-specific promoter. The chimeric CEA promoter (CC promoter), which contained an enhancer from the immediate early gene of cytomegalovirus and the CEA promoter, achieved 4- to 5-fold higher transgene expression in CEA-producing cells than the original CEA promoter while maintaining CEA specificity. Furthermore, a complex of a monoclonal antibody against Lewis Y antigen (LYA), the CC promoter-containing plasmid and cationic liposomes (DOTAP) achieved specific gene expression in CEA-producing and LYA-positive adenocarcinoma cell lines that was 200-fold more efficient than in CEA-non-producing and LYA-negative cell lines during a short in vitro incubation. This strategy may be applicable for clinical gene therapy. 相似文献